Brief: AB Science Shares New Research Results On Masitinib
13/03/2024 13:02
March 13 (Reuters) - AB Science SA ABS.PA :
* NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE
IN A
MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE
* FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM
NEUROFILAMENT
LIGHT CHAIN, AN IMPORTANT BIOMARKER FOR NEURODEGENERATIVE
DISORDERS
Source text for Eikon: urn:newsml:reuters.com:*:nGNX71C4Gp
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansknewsroom@thomsonreuters.com; + 48 58 7785110;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041